Core Insights - MannKind Corporation has successfully completed the acquisition of scPharmaceuticals Inc, which is expected to diversify and accelerate its revenue growth, particularly through the innovative therapy FUROSCIX for edema related to chronic heart failure and chronic kidney disease [1][2] - The acquisition enhances MannKind's commercial and medical capabilities by integrating scPharmaceuticals' experienced team, positioning the company for further growth in cardiometabolic care [2] - MannKind's annualized revenue run rate exceeds $370 million based on Q2 2025 results, driven by its commercial assets including Afrezza, FUROSCIX, and V-Go [1] Acquisition Details - The acquisition was structured as a tender offer at a price of $5.35 per share in cash, plus a non-tradable contingent value right (CVR) for potential milestone payments, totaling up to $6.35 per share [3] - Approximately 73.47% of scPharmaceuticals' outstanding shares were tendered, allowing the transaction to proceed, with scPharmaceuticals becoming a wholly owned subsidiary of MannKind [4] - Following the acquisition, scPharmaceuticals' common stock ceased trading on Nasdaq [5] Strategic Fit and Future Growth - The strategic alignment between MannKind and scPharmaceuticals creates significant growth opportunities by combining MannKind's endocrinology expertise with scPharmaceuticals' cardiovascular capabilities [2] - MannKind aims to expand FUROSCIX's market reach among nephrologists and cardiologists, enhancing its position in chronic heart failure treatment [2] - The company has a late-stage pipeline that includes Inhaled Clofazimine and nintedanib DPI, which supports long-term value creation [2]